EPISODE · Mar 3, 2026 · 3 MIN
EP 117.2026 准入变局，当一品两规松绑，药企如何抢占临床导向的新红利
from MedVerse医路人
🔓 2026 年，医药行业迎来了久违的松绑时刻。随着 12 个省市相继取消“一品两规”限制，国谈创新药的入院壁垒正在瓦解。本期播客将深度剖析这一政策背后的松绑与加压辩证法：一方面是入院名额的放开，另一方面是医保基金与 DRG/DIP 的支付硬约束。我们将复盘河北等地的先行经验，探讨跨国药企如何利用临购备案等绿色通道，实现创新药的快速放量。🏥 政策红利与实战应对： 告别数量红线 四大破局措施 医保承压与支付博弈 2026 药企布局新策略 未来演进关于节目《MedVerse 医路人》是一档聚焦医药行业职业发展、市场与学术推广、以及行业趋势观察的播客。我们希望通过行业解析、案例分享与对话讨论，帮医药人看清职场成长的底层逻辑，找到更清晰的发展路径。找到我们公众号：MedVerse Pro小红书：达利Dali收听渠道：小宇宙、苹果Podcast、QQ音乐*扣子空间前往小宇宙评论区与主播互动
Embed this episode
Ready to play
EP 117.2026 准入变局，当一品两规松绑，药企如何抢占临床导向的新红利
0:00
3:15
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MedVerse医路人?
This episode is 3 minutes long.
When was this MedVerse医路人 episode published?
This episode was published on March 3, 2026.
Can I download this MedVerse医路人 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!